Pherecydes Pharma SA
Developing bacterial phages as anti-infectives
Scientists have long realized that certain viruses can destroy bacteria. Classified as bacteriophages, these viruses attach to specific receptors on the surface of bacteria and inject their own genetic material. Some so-called lytic phages kill their hosts right away and their progeny replicate as soon as the bacteria are lysed, or ruptured. Pherecydes Pharma SA, a start-up based in Romainville, France, is working to identify and modify large numbers of lytic phages, with the goal of creating therapies effective against antibiotic-resistant nosocomial infections.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains